Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The emerging role of PI3K inhibitors for solid tumour treatment and beyond.

British journal of cancer - 1 Jun 2023

Belli Carmen, Repetto Matteo, Anand Santosh, Porta Camillo, Subbiah Vivek, Curigliano Giuseppe

Abstract excerpt

Phosphoinositide 3-kinases (PI3Ks) play a central role in tumourigenesis with recurrent activating mutations of its p110α subunit (PIK3CA) identified in several tumours. Although several PI3K inhibitors are approved for haematological malignancies, only alpelisib was approved in solid tumours and for the treatment of PIK3CA-related overgrowth spectrum (PROS) syndrome. Traditional PI3K inhibitors inhibit both...

Topics

Join the communities discussing this publication.

Class I Phosphatidylinositol 3-Kinases
Mutation
Neoplasms
Phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 36914722
DOI: 10.1038/s41416-023-02221-1
PMCID: PMC10241926

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The emerging role of PI3K inhibitors for solid tumour treatment and beyond.PMID 36914722Read ↗

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid TumorsSemantic proximity Read ↗

Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.Semantic proximity Read ↗

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.Semantic proximity Read ↗

Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).Semantic proximity Read ↗

Current State and Future Challenges for PI3K Inhibitors in Cancer TherapySemantic proximity Read ↗

Targeting PI3K in cancer: mechanisms and advances in clinical trialsSemantic proximity Read ↗

p110δ PI3K as a therapeutic target of solid tumoursSemantic proximity Read ↗

Targeting PI3K in Cancer: Any Good News?Semantic proximity Read ↗

Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?Semantic proximity Read ↗

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.Semantic proximity Read ↗

Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020).Semantic proximity Read ↗

Advances in subunits of PI3K class I in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.